Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.

We also noted that by day 40 there were fewer additional tumours in both the MMTV-NIC PTEN +/+ and MMTV-NIC PTEN +/− animals treated with AZD8931, and although this did not reach statistical significance the reduction in tumour burden was greater in the MMTV-NIC PTEN +/+ mice, consistent with the increased sensitivity of the MMTV-NIC PTEN +/+ tumours to AZD8931 (median values for tumours per mouse: MMTV-NIC PTEN +/+ , vehicle=5; MMTV-NIC PTEN +/+ , AZD8931=1; MMTV-NIC PTEN +/− , vehicle=6; MMTV-NIC PTEN +/− , AZD8931=3; P =0.1025, Kruskal–Wallis).

also in 111,027 other papers